ADMA Biologics to Present at Jefferies 2017 Healthcare Conference RAMSEY, N.J.

ADMA Biologics to Present at Jefferies

2017 Healthcare Conference

RAMSEY, N.J. - May 25, 2017 -

ADMA Biologics, Inc. (NASDAQ: ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize

specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases,

today announced that Adam Grossman, President and CEO is scheduled to provide a corporate overview at the Jefferies 2017 Healthcare

Conference on June 8, 2017 at 8:30 AM ET.

A live webcast may be accessed under the "Investor Relations"

tab on the Company's website at www.admabiologics.com. A replay of the webcast will be available after the conclusion of

About ADMA Biologics, Inc. (ADMA)

ADMA is a late-stage biopharmaceutical company that develops,

manufactures and intends to commercialize specialty plasma-based biologics for the proposed treatment of Primary Immune Deficiency

Disease (PIDD) and the prevention and treatment of certain infectious diseases. ADMA's mission is to develop and commercialize

plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious

diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency

disease, or who may be immune-compromised for medical reasons. ADMA has received U.S. Patent 9,107,906 relating to certain aspects

of its product candidate. ADMA has announced the signing of a definitive agreement to acquire certain assets from Biotest Pharmaceuticals

Corporation (BPC) which closing of the transaction is expected to take place in June 2017. For more information, please visit www.admabiologics.com.

Forward-Looking Statements

This press release contains "forward-looking statements"

pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include,

without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and

may contain the words "estimate," "intend," "target," "will," "is likely,"

"would," "may," or, in each case, their negative, or words or expressions of similar meaning. These forward-looking

statements include, but are not limited to, statements concerning our ability to develop, manufacture, and commercialize specialty

plasma-based biologics for the proposed treatment of immune deficiencies and the prevention of certain infectious diseases, the

success of our work with our third party vendors and the U.S. Food and Drug Administration in furtherance of and progress towards

an approval of our Biologics License Application for specialty plasma-based biologics and the ability of such third parties to

respond adequately or in a timely manner to the issues raised by the FDA, our ability to successfully pursue commercialization

and prelaunch activities, the timeframe within which we may receive approval from the FDA for specialty plasma-based biologics,

if at all, the potential of our specialty plasma-based biologics to provide meaningful clinical improvement for patients living

with PIDD or other indications and our ability to realize increased prices for plasma growth in the plasma collection industry.

These forward-looking statements also involve risks and uncertainties concerning our ability to complete and close the proposed

transaction to acquire certain assets from Biotest Pharmaceuticals Corporation described in certain of our 2017 filings with the

U.S. Securities and Exchange Commission, the expected closing date of such transaction, the anticipated benefits and synergies

of such transaction, anticipated future combined businesses, operations, products and services, and liquidity, debt repayment and

capital return expectations. Actual events or results may differ materially from those described in this document due to a number

of important factors. These factors include, among others, the outcome of regulatory reviews of the proposed transaction; the ability

of the parties to complete the transaction; the ability of ADMA to successfully integrate the to-be acquired therapy business,

operations (including manufacturing and supply operations), sales and distribution channels, business and financial systems and

infrastructures, research and development, technologies, products, services and employees; the ability of the parties to retain

their customers and suppliers; the ability of the parties to minimize the diversion of their managements' attention from

ongoing business matters; ADMA's ability to manage the increased scale, complexity and globalization of its business, operations

and employee base post-closing, among others. Forward-looking statements are subject to many risks and uncertainties that could

cause our actual results and the timing of certain events to differ materially from any future results expressed or implied by

the forward-looking statements, including those risks and uncertainties described in our filings with the U.S. Securities and Exchange

Commission, including our most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Therefore, current

and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included

in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements

included herein, the inclusion of such information should not be regarded as a representation or warranty by ADMA or any other

person that the objectives and plans of ADMA will be achieved in any specified time frame, if at all. Except to the extent required

by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions

to any of the forward-looking statements.

Vice President and Chief Financial Officer |201-478-5552 | www.admabiologics.com